Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Sigilon Therapeutics Inc is a biotechnology business based in the US. Sigilon Therapeutics Inc shares (SGTX) are listed on the NASDAQ and all prices are listed in US Dollars. Sigilon Therapeutics Inc employs 66 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $0.77 |
|---|---|
| 52-week range | $0.73 - $10.54 |
| 50-day moving average | $0.93 |
| 200-day moving average | $2.60 |
| Wall St. target price | $3.95 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.25 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.765 from 2022-07-01
| 1 week (2022-06-28) | -7.83% |
|---|---|
| 1 month (2022-06-06) | -12.27% |
| 3 months (2022-04-06) | -49.67% |
| 6 months (2022-01-06) | -69.64% |
| 1 year (2021-07-06) | -92.14% |
|---|---|
| 2 years (2020-07-02) | N/A |
| 3 years (2019-07-02) | N/A |
| 5 years (2017-07-02) | N/A |
| Revenue TTM | $9.8 million |
|---|---|
| Gross profit TTM | $-54,270,000 |
| Return on assets TTM | -26.23% |
| Return on equity TTM | -74.58% |
| Profit margin | 0% |
| Book value | $1.99 |
| Market capitalisation | $24.8 million |
TTM: trailing 12 months
We're not expecting Sigilon Therapeutics Inc to pay a dividend over the next 12 months.
Sigilon Therapeutics, Inc. , a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.